Structured Abstract
Importance Post-acute sequelae of SARS-CoV-2 infection (PASC) is emerging as a major public health issue.
Objective We characterized the incidence of PASC, or related symptoms and diagnoses, for COVID-19 and influenza patients.
Design Retrospective cohort study.
Setting Our data sources were the IBM MarketScan Commercial Claims and Encounters (CCAE), Optum Electronic Health Record (EHR) and Columbia University Irving Medical Center (CUIMC) databases that were transformed to the Observational Medical Outcome Partnership (OMOP) Common Data Model (CDM) and were part of the Observational Health Sciences and Informatics (OHDSI) network.
Participants The COVID-19 cohort consisted of patients with a diagnosis of COVID-19 or positive lab test of SARS-CoV-2 after January 1st 2020 with a follow up period of at least 30 days. The influenza cohort consisted of patients with a diagnosis of influenza between October 1, 2018 and May 1, 2019 with a follow up period of at least 30 days.
Intervention Infection with COVID-19 or influenza.
Main Outcomes and Measures Post-acute sequelae of SARS-CoV-2 infection (PASC), or related diagnoses, for COVID-19 and influenza patients.
Results In aggregate, we characterized the post-acute experience for over 440,000 patients who were diagnosed with COVID-19 or tested positive for SARS-COV-2. The long term sequelae that had a higher incidence in the COVID-19 compared to Influenza cohorts were altered smell or taste, myocarditis, acute kidney injury, dyspnea and alopecia. Additionally, the long term incidences of respiratory illness, musculoskeletal disease, and psychiatric disorders for the COVID-19 population were higher than expected.
Conclusions and Relevance The long term sequelae of COVID-19 and influenza may be different. Further characterization of PASC on large scale observational healthcare databases is warranted.
Competing Interest Statement
Dr. Ryan is employee of Janssen Research and Development, and shareholder of Johnson & Johnson.
Funding Statement
This research was funded by a grant from National Library of Medicine (R01 LM006910).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This OHDSI network COVID-19 research is approved under Columbia University Irving Medical Center IRB# AAAO7805. Some databases used (IBM MarketScan CCAE and Optum EHR) in these analyses are commercially available, syndicated data assets that are licensed by contributing authors for observational research. These assets are de-identified commercially available data products that could be purchased and licensed by any researcher. The collection and de-identification of these data assets is a process that is commercial intellectual property and not privileged to the data licensees and the co-authors on this study. Licensees of these data have signed Data Use Agreements with the data vendors which detail the usage protocols for running retrospective research on these databases. All analyses performed in this study were in accordance with Data Use Agreement terms as specified by the data owners. As these data are deemed commercial assets, there is no Institutional Review Board applicable to the usage and dissemination of these result sets or required registration of the protocol with additional ethics oversight. Compliance with Data Use Agreement terms, which stipulate how these data can be used and for what purpose, is sufficient for the licensing commercial entities. Further inquiry related to the governance oversight of these assets can be made with the respective commercial entities: IBM (www.ibm.com) and Optum (optum.com). At no point in the course of this study were the authors of this study exposed to identified patient-level data. All result sets represent aggregate, de-identified data that are represented at a minimum cell size of >5 to reduce potential for re-identification. Furthermore, the New England Institutional Review Board of Janssen Research & Development (Raritan, NJ) has determined that studies conducted on licensed copies of IBM MarketScan CCAE and Optum EHR are exempt from study-specific IRB review, as these studies do not qualify as human subjects research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Optum EHR and MarketScan CCAE are deidentified datasets available for licensure by Optum and IBM, respectively. The research done with data from Columbia University Irving Medical Center was approved by the IRB.